Ketanserin

A high-affinity, non-selective antagonist of 5-HT2 receptor with Ki of 2-3 nM for 5-HT2A and 28 nM for 5-HT2C; also has a high affinity antagonist for the H1 receptor (Ki= 2 nM) and α1-adrenergic receptor (Ki=40 nM) ; an antihypertensive agent.Hypertension Approved (In Vitro) :Ketanserin at 0.3 μM inhibits the voltage-dependent step current (IhERG.step) and tail current (IhERG.tail) of hERG channels with a 5-min exposure. The synergistic effect observed for AA with 5-HT is, also, blocked by the 5-HT receptor blockers cyproheptadine (IC50=22.0±7 μM), Ketanserin (IC50=152±23 μM) . Ketanserin (50-350 μM) inhibits the synergism by blocking the receptor in a dose-dependent manner. The IC50 value of Cyproheptadine is 22±7 μM and Ketanserin is 152±23 μM. Ketanserin inhibits platelet aggregation with an IC50 of 240 (169-339) nM. (In Vivo) :Ketanserin is a 5-HT2A receptor antagonist. Ketanserin significantly reduces BDNF protein levels in numerous brain regions (CA1 and CA3 of the hippocampus, prefrontal cortex, central amygdaloid nucleus, dorsomedial hypothalamic nucleus, dentate gyrus, shell of the nucleus accumbens and midbrain periaqueductal gray) . 5-HT2A antagonist Ketanserin can significantly reduce BDNF mRNA levels in various brain regions.

74050-98-9

R41468

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO: 8 mg/mL

O=C (N1CCN2CCC (C (C3=CC=C (F) C=C3) =O) CC2) NC4=C (C=CC=C4) C1=O

C22H22FN3O3

395.4268

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.